NVS

Novartis AG 2008 Financial Summary (Form 6-K)

Business Context and Reporting Period

This Form 6-K, dated January 28, 2009, reports the full-year 2008 and fourth-quarter 2008 results for Novartis AG, a global healthcare company headquartered in Basel, Switzerland. The reporting period covers continuing operations across Pharmaceuticals, Vaccines and Diagnostics, Sandoz (generics), and Consumer Health. The results reflect a strategic shift toward a focused healthcare portfolio following the divestment of the Gerber and Medical Nutrition businesses in 2007.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales rose 9% (5% in local currencies), driven by volume growth (+6 pts) and positive currency translation (+4 pts). Pharmaceuticals returned to dynamic growth (+10%), while Vaccines and Diagnostics grew 21%.
• Profitability Surge: Operating income increased 32% to USD 9.0 billion. This growth was aided by the absence of the USD 1.0 billion in exceptional charges recorded in 2007 (environmental provisions and Forward restructuring costs). Excluding these 2007 charges, operating income grew 15%.
• Alcon Acquisition Impact: In July 2008, Novartis acquired a 25% stake in Alcon Inc. for USD 10.4 billion. This transaction introduced financing costs that reduced net financial income and contributed to a shift from net liquidity to net debt.
• Discontinued Operations: 2007 results included USD 5.4 billion in net proceeds from the divestment of Gerber and Medical Nutrition. 2008 results from discontinued operations were minimal (USD 70 million).

Guidance, Outlook, and Risks

• 2009 Outlook: Management expects another year of record net sales and earnings. Net sales are projected to grow at a mid-single-digit rate in local currencies, with Pharmaceuticals expected to grow at a mid- to high-single-digit rate.
• Dividend: The Board proposed a dividend of CHF 2.00 per share for 2008, a 25% increase from 2007, representing a payout ratio of 53% of net income from continuing operations.
• R&D Pipeline: The company submitted 14 major regulatory filings in 2008, including Afinitor (kidney cancer), Menveo (meningitis vaccine), and QAB149 (COPD). R&D spending rose to 21.7% of net sales in the Pharmaceuticals division.
• Risks and Contingencies:
  • Patent Expirations: Anticipated loss of patent protection for Diovan starting in 2011 (Europe) and 2012 (US).
  • Legal Proceedings: Ongoing litigation regarding Zometa/Aredia (osteonecrosis of the jaw), Trileptal (off-label promotion), and Average Wholesale Price (AWP) claims.
  • Alcon Valuation: A 37% decline in Alcon's share price in 2008 triggered an impairment test; however, no charge was recorded as the "value in use" exceeded the carrying value.

Investor Verification Checklist

• Alcon Investment: Verify the valuation assumptions used in the impairment test for the 25% Alcon stake, given the significant drop in Alcon's market price.
• Adjusted vs. Reported Earnings: Compare reported earnings against "adjusted" figures to understand the impact of the 2007 exceptional charges and 2008 restructuring costs.
• Currency Sensitivity: Assess the impact of volatile currency markets, which negatively impacted Q4 sales by 7 percentage points despite strong volume growth.
• Patent Cliff Mitigation: Review the progress of the Oncology pipeline and emerging market expansion strategies designed to offset the upcoming Diovan patent expiration.
• Legal Exposure: Monitor the status of the Trileptal off-label promotion settlement discussions and Zometa litigation outcomes.